Tens of thousands of U.S. travelers, military personnel, and aid workers line up for yellow fever shots each year, and for decades they have depended on a single licensed vaccine: YF-VAX. When manufacturing problems pulled that product off shelves between 2017 and 2019, clinics scrambled, appointments were canceled, and the federal government resorted to importing doses from overseas under an emergency regulatory workaround. Now, a Phase 2 clinical trial published in the New England Journal of Medicine in 2025 shows that Sanofi’s investigational replacement, called vYF, triggers an immune response and safety profile statistically indistinguishable from YF-VAX in U.S. adults, a result that could eventually give the country a second domestic option and a more resilient supply chain.
What the Phase 2 trial found
The randomized, observer-blind study, registered on ClinicalTrials.gov as NCT04942210, enrolled adults across the United States and assigned them to receive either vYF or YF-VAX. Researchers measured the standard benchmarks for yellow fever vaccine performance: geometric mean titers (GMTs) of neutralizing antibodies, seroconversion rates, and seroprotection rates.
On every primary endpoint, vYF met the pre-specified threshold for non-inferiority. Seroprotection rates after a single dose were essentially identical between the two groups at the primary assessment time point. GMTs of neutralizing antibodies fell well within the margins regulators use to confirm that a new vaccine performs comparably to an established one. In practical terms, the immune defenses vYF built in study participants were statistically on par with those generated by the vaccine clinicians have trusted for years.
The safety picture was similarly reassuring. Participants in both arms reported the kinds of transient reactions familiar to anyone who has received a live attenuated yellow fever vaccine: soreness at the injection site, headache, fatigue, and occasional low-grade fever. Serious adverse events were rare in both groups and were judged unrelated or unlikely related to vaccination. Shifting to a new manufacturing platform, in other words, did not introduce new safety signals.
“These results demonstrate that the Vero-cell-derived vYF vaccine is immunologically non-inferior to YF-VAX, supporting its potential as a viable alternative for yellow fever prevention,” the trial investigators wrote in the NEJM publication.
How vYF is made, and why that matters
The critical difference between vYF and YF-VAX is not the vaccine strain itself, which remains the well-characterized 17D lineage, but how it is grown. YF-VAX is produced in embryonated chicken eggs, a process that has worked for decades but carries inherent scaling limits. Sourcing specific pathogen-free eggs in large quantities is logistically complex, batch-to-batch variability is difficult to eliminate, and a single contamination event can shut down production for months.
vYF is instead manufactured using Vero cells, a continuous cell line already employed in the production of other licensed vaccines, including some polio and rabies products. Vero-based manufacturing uses standardized bioreactor processes that can be scaled up more flexibly when demand spikes, whether from an outbreak in an endemic region or a sudden jump in international travel requirements. If vYF reaches the market, this platform difference could be the factor that prevents a repeat of the supply crises that left U.S. travelers without reliable access to yellow fever vaccination.
The evidence trail leading to Phase 2
The latest results build on a body of earlier work. A Phase 1 dose-ranging study had already tested multiple dose levels of vYF in healthy adults, documenting high seroconversion rates and a reactogenicity profile consistent with existing yellow fever vaccines. Most adverse events were mild to moderate and resolved without treatment. Critically, investigators saw no signal of the rare but serious viscerotropic or neurotropic disease that regulators watch for closely with any yellow fever vaccine candidate.
A separate Phase 1 study (registered as NCT04142086) went deeper, comparing the innate and adaptive immune signatures triggered by vYF and YF-VAX. Published in eBioMedicine, that research found the two vaccines activated matching transcriptomic pathways on a nearly identical timeline. The finding matters because it suggests vYF does not merely produce the right antibody numbers; it engages the same biological defense mechanisms as the licensed product.
Before any human received a dose, preclinical work in cynomolgus macaques, published in the journal Vaccine, confirmed that vYF-vaccinated animals were protected when challenged with yellow fever virus and that the 17D strain’s attenuation remained stable under the Vero-cell manufacturing process.
A single point of failure in U.S. vaccine supply
YF-VAX remains the only yellow fever vaccine licensed in the United States, according to the FDA’s product page. That single-source status has already caused real disruption. During the shortage that began in 2017, the Centers for Disease Control and Prevention coordinated the importation of STAMARIL, Sanofi’s egg-based yellow fever vaccine licensed in other countries, under an expanded access investigational new drug (IND) program. Enhanced safety surveillance during that period confirmed that serious adverse events remained rare, but the arrangement was a stopgap, not a solution.
For travelers, the shortage meant fewer authorized vaccination sites, longer wait times, and, in some cases, postponed trips. For public health planners managing outbreak response in Africa and South America, competition for limited global doses added another layer of complexity. A second domestically licensed product, particularly one built on a more scalable manufacturing platform, would reduce the risk that any single production failure leaves the country exposed.
What still needs to happen before licensure
Promising as the Phase 2 data are, they represent a mid-stage milestone. No Phase 3 trial results for vYF have been published as of May 2026, and long-term durability data, the kind that would confirm protection lasting years rather than weeks, are not yet available. The ClinicalTrials.gov registry entry does not specify a timeline for regulatory submission or potential FDA review.
Pediatric data are also absent. Every published human trial of vYF has enrolled adults, leaving an open question about performance in children, a population the Advisory Committee on Immunization Practices (ACIP) considers when issuing travel vaccination recommendations. Without pediatric studies, any initial licensure would likely carry age restrictions, limiting the vaccine’s reach for family travel and for campaigns targeting younger populations in endemic countries.
The regulatory pathway itself is unresolved. Whether Sanofi will seek a Biologics License Application on the strength of Phase 2 immunobridging data alone, or whether the FDA will require a larger Phase 3 trial, has not been publicly disclosed. Regulators have occasionally accepted robust immunobridging evidence for vaccines against diseases where traditional efficacy trials are impractical, but each product is judged individually. For a live attenuated yellow fever vaccine, demonstrating that a new formulation behaves like the established 17D-based products across antibody levels, safety profiles, and mechanistic immune signatures may carry particular weight in that decision.
If vYF does reach the market, ACIP would need to address practical questions: Can it be used interchangeably with YF-VAX? Are there different contraindications for people with egg allergies? How should clinicians handle patients previously vaccinated with an egg-based product? Those policy decisions will depend on the current adult data, post-authorization safety monitoring, and results from studies in broader populations that have not yet been conducted.
Where vYF stands in the path toward a second U.S. yellow fever vaccine
The Phase 2 trial establishes that a Vero-cell yellow fever vaccine can match YF-VAX on the measures that matter most: neutralizing antibody response, seroprotection, and clinical safety in adults. That finding, layered on top of consistent Phase 1 and preclinical evidence, makes vYF the most advanced candidate positioned to break the United States’ dependence on a single yellow fever vaccine. The distance between a strong Phase 2 readout and a licensed product on clinic shelves, however, remains significant. Durability data, pediatric trials, and a clear regulatory strategy will determine whether vYF becomes a practical tool for stabilizing vaccine supply or remains a promising data set waiting for its next chapter.
More from Morning Overview
*This article was researched with the help of AI, with human editors creating the final content.
